Webinar | How Will Microbiome Reshape Anti-Aging Skin Care in 2026 Register Here

Ardelyx

Ardelyx develops novel oral therapeutics to treat mineral metabolism and metabolic disorders.
2007
251-500
Fremont, California, United States

Investment Funding

Last Funding Stage

Post-IPO Debt

Total Funding Amount

557.68M

Last Funding Amount

20.M

Last Funding Date

30-06-2022

Startup Stage

IPO

Lead Investors

New Enterprise Associates, RA Capital Management, Cormorant Asset Management, Perceptive Advisors, HealthCare Royalty Partners

Revenue

$100M to $500M

People

Founders

Something missing or incorrect on this page? Help us enrich this information